Diagnostic Work‑Up for Suspected IgA Multiple Myeloma with Renal Impairment

Initial Laboratory Assessment

• Obtain serum protein electrophoresis (SPEP) with immunofixation, serum free‑light‑chain (FLC) assay, quantitative immunoglobulins (IgG, IgA, IgM) by nephelometry, complete blood count with differential, serum creatinine and eGFR, serum calcium, and a full skeletal radiographic survey as the first‑line work‑up for a patient with suspected IgA myeloma and renal dysfunction. 1

• Quantitative immunoglobulin measurement (IgG, IgA, IgM) by nephelometry provides the absolute IgA level and aids in disease classification. [1][2]

• The serum FLC assay with involved/uninvolved ratio increases diagnostic sensitivity and is required for complete response assessment in myeloma. [2][3]

• 24‑hour urine collection for total protein, urine protein electrophoresis (UPEP) and urine immunofixation (UIFE) is mandatory to quantify urinary light chains (Bence‑Jones protein); random urine specimens are insufficient. [1][3]

• Serum FLC testing cannot replace a 24‑hour UPEP when measurable urinary M‑protein is present. 2

• Serum electrolytes should be measured to identify metabolic derangements that may accompany renal impairment. [1][4]

• Urinalysis is part of the baseline evaluation to detect proteinuria and hematuria. 2

• Anemia assessment: hemoglobin < 10 g/dL or ≥ 2 g/dL below the lower limit of normal defines myeloma‑related anemia. [1][4]2

• Hypercalcemia is defined as serum calcium > 11.5 mg/dL within the CRAB criteria. [1][4]

• Serum albumin, β‑2 microglobulin, and lactate dehydrogenase (LDH) are required for International Staging System (ISS) staging and prognostication. [2][3]

Bone Marrow Evaluation

• Perform unilateral bone‑marrow aspiration and/or trephine biopsy; ≥ 10 % clonal plasma cells is the diagnostic threshold for multiple myeloma. [1][4]

• CD138 immunostaining on the biopsy improves accuracy of plasma‑cell percentage determination. 3

• Clonality confirmation by immunoperoxidase or immunofluorescence demonstrating monoclonal IgA (λ or κ) in plasma‑cell cytoplasm is required for definitive diagnosis. 3

• Cytogenetic/FISH studies (standard karyotype and probes for del(17p), t(4;14), t(14;16), t(14;20), gain 1q, del 1p) identify high‑risk abnormalities that markedly influence prognosis and treatment choice. [1][3]

• Flow‑cytometric immunophenotyping may be performed but cannot replace morphologic plasma‑cell quantification. 3

Imaging Studies

• Conduct a full skeletal radiographic survey (spine, pelvis, skull, humeri, femurs) to detect lytic bone lesions. [1][4]2

• MRI or CT of symptomatic sites should be added even if the skeletal survey is negative, especially when bone pain or neurologic symptoms are present. [1][4]

• MRI of the spine is mandatory when spinal‑cord compression is suspected. [1][4]

Renal Biopsy Considerations

• Kidney biopsy is indicated when non‑selective proteinuria (predominantly albuminuria) or an involved serum FLC level < 500 mg/L is observed, as these findings suggest renal lesions other than classic light‑chain cast nephropathy (e.g., MIDD, AL amyloidosis, proliferative glomerulonephritis with monoclonal Ig deposits). 5

Diagnostic Criteria for Symptomatic Multiple Myeloma

• Diagnosis requires both:

  • Calcium > 11.5 mg/dL,
  • Renal insufficiency (serum creatinine > 2 mg/dL or creatinine clearance < 40 mL/min),
  • Anemia (hemoglobin < 10 g/dL or ≥ 2 g/dL below LLN),
  • Bone lesions (lytic lesions, severe osteopenia, or pathologic fractures). [1][4]

• In a patient with renal impairment meeting the “R” criterion and ≥ 10 % clonal plasma cells, symptomatic myeloma is established. [1][4]

Differential Diagnosis

• Smoldering multiple myeloma: serum IgA ≥ 3 g/dL and/or clonal plasma cells ≥ 10 % without CRAB features. [1][4]

• Monoclonal gammopathy of undetermined significance (MGUS): serum M‑protein < 3 g/dL, clonal plasma cells < 10 %, and no end‑organ damage. [1][4]

Critical Pitfalls & Best Practices

• Always perform immunofixation on both serum and urine specimens, even when electrophoresis shows no visible M‑protein, to avoid missing light‑chain‑only disease. 3

• Do not rely on random urine samples for M‑protein quantification; a properly collected 24‑hour urine is required. 3

• Serum FLC assay alone cannot replace a 24‑hour UPEP in patients with measurable urinary M‑protein. 2

• Obtain cytogenetic/FISH studies on all bone‑marrow samples because high‑risk abnormalities (del(17p), t(4;14), t(14;16), etc.) fundamentally alter prognosis and therapeutic decisions. [1][3]

• Consider advanced imaging (MRI/CT) even when the skeletal survey is negative if clinical symptoms suggest bone involvement. [1][4]

• Evaluate for renal biopsy when non‑selective proteinuria or low involved FLC (< 500 mg/L) is present, as this may indicate a renal lesion requiring disease‑specific management. 5

Diagnostic Criteria and Evaluation of Multiple Myeloma

1. Core Diagnostic Requirements

• The International Myeloma Working Group (IMWG) defines multiple myeloma as the presence of ≥10 % clonal bone‑marrow plasma cells (or a biopsy‑proven plasmacytoma) together with end‑organ damage (CRAB) or myeloma‑defining biomarkers. 6

2. Essential Laboratory Tests

2.1 Monoclonal Protein Detection

• Serum protein electrophoresis (SPEP) with immunofixation is required to detect and characterize the M‑protein. 6
• 24‑hour urine protein electrophoresis (UPEP) with immunofixation is mandatory for quantifying urinary M‑protein. 6
• Serum free‑light‑chain (FLC) assay with involved/uninvolved ratio adds sensitivity and is essential for documenting stringent complete response, but it cannot replace 24‑hour UPEP for monitoring measurable urinary M‑protein. 7
• Nephelometric quantification of IgG, IgA, and IgM provides additional immunoglobulin profiling. 6

2.2 Bone‑Marrow Evaluation

• Bone‑marrow aspiration/biopsy must be performed to quantify clonal plasma cells; a threshold of ≥10 % confirms disease. 6
• Cytogenetic studies with fluorescence‑in‑situ hybridisation (FISH) are required on all marrow samples to identify high‑risk abnormalities (del(17p), t(4;14), t(14;16), t(14;20), gain 1q, del 1p, p53 mutation). 6
• Immunophenotypic and molecular investigations on marrow specimens aid in disease classification. 8

2.3 Routine Laboratory Panel

• Complete blood count with differential and peripheral smear (search for rouleaux formation and circulating plasma cells). 7
• Serum creatinine and calculated creatinine clearance to assess renal function. 7
• Serum calcium – hypercalcemia is defined as > 11.5 mg/dL. 6
• Serum albumin, β‑2 microglobulin, and lactate dehydrogenase (LDH) are used for staging and prognostication. 7

3. Imaging Studies

• Conventional skeletal radiographic survey (spine, pelvis, skull, humeri, femurs) remains the baseline imaging modality. 6
• MRI or CT of symptomatic sites is recommended even if the skeletal survey is negative; MRI is mandatory when spinal cord compression is suspected. 6
• Advanced imaging (MRI/CT/PET‑CT) should be considered when clinical symptoms suggest bone involvement despite a negative survey. 8

4. Diagnostic Criteria for Symptomatic Myeloma (CRAB)

In the absence of CRAB, any of the following myeloma‑defining biomarkers also establishes symptomatic disease: bone‑marrow plasma cells *≥ 60 %, serum involved/uninvolved FLC ratio ≥ 100 (with involved FLC ≥ 100 mg/L), or > 1 focal lesion* on MRI (≥ 5 mm). (These biomarkers are cited in the IMWG guideline but the specific citations are omitted in the source text; therefore they are not listed here.)

5. Differential Diagnosis

• Monoclonal gammopathy of undetermined significance (MGUS) is defined by a serum monoclonal protein < 3 g/dL (other criteria lack cited references). 9
• Smoldering multiple myeloma requires serum monoclonal protein ≥ 3 g/dL and/or clonal bone‑marrow plasma cells ≥ 10 % without CRAB features. 9

6. Critical Pitfalls and Best‑Practice Recommendations

• Do not use random urine samples for M‑protein quantification; a properly collected 24‑hour urine is mandatory. 9
• Always perform immunofixation even when electrophoresis shows no visible peak, to avoid missing light‑chain‑only myeloma. 9
• Serum FLC assay alone should not replace 24‑hour UPEP in patients with measurable urinary M‑protein. 7
• Nephelometric quantitation may overestimate monoclonal protein concentrations when levels are high. 9
• Obtain cytogenetic/FISH studies on all bone‑marrow samples because high‑risk features fundamentally alter prognosis and treatment decisions. 6
• Consider advanced imaging (MRI/CT/PET‑CT) even with a negative skeletal survey if clinical symptoms suggest bone involvement. 8